Loading...

Biocon

NSEI:BIOCON
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BIOCON
NSEI
₹306B
Market Cap
  1. Home
  2. IN
  3. Pharmaceuticals & Biotech
Company description

Biocon Limited, a biopharmaceutical company, develops, manufactures, and sells biopharmaceuticals for diabetes, cancer, and autoimmune conditions. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
  • Biocon has significant price volatility in the past 3 months.
BIOCON Share Price and Events
7 Day Returns
-2.8%
NSEI:BIOCON
-1.6%
IN Biotechs
4.3%
IN Market
1 Year Returns
-20.9%
NSEI:BIOCON
-18.1%
IN Biotechs
0.3%
IN Market
BIOCON Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Biocon (BIOCON) -2.8% -16.8% -17.8% -20.9% 133% 257.7%
IN Biotechs -1.6% -13.4% -14.7% -18.1% 134% 232.5%
IN Market 4.3% -1.1% 6.7% 0.3% 36.5% 45.2%
1 Year Return vs Industry and Market
  • BIOCON underperformed the Biotechs industry which returned -18.1% over the past year.
  • BIOCON underperformed the Market in India which returned 0.3% over the past year.
Price Volatility
BIOCON
Industry
5yr Volatility vs Market
Related Companies

BIOCON Value

 Is Biocon undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Biocon to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Biocon.

NSEI:BIOCON Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 17 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 18.7%
Perpetual Growth Rate 10-Year IN Government Bond Rate 7.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NSEI:BIOCON
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year IN Govt Bond Rate 7.6%
Equity Risk Premium S&P Global 8.6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.38
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.384 (1 + (1- 35%) (5.88%))
1.293
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.29
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 7.55% + (1.293 * 8.6%)
18.67%

Discounted Cash Flow Calculation for NSEI:BIOCON using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Biocon is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NSEI:BIOCON DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (INR, Millions) Source Present Value
Discounted (@ 18.67%)
2019 3,039.50 Analyst x2 2,561.36
2020 3,164.33 Analyst x3 2,247.09
2021 11,127.25 Analyst x4 6,658.78
2022 12,952.00 Analyst x1 6,531.50
2023 14,620.40 Est @ 12.88% 6,213.04
2024 16,269.87 Est @ 11.28% 5,826.37
2025 17,923.27 Est @ 10.16% 5,408.79
2026 19,604.23 Est @ 9.38% 4,985.42
2027 21,335.30 Est @ 8.83% 4,572.14
2028 23,137.29 Est @ 8.45% 4,178.33
Present value of next 10 years cash flows ₹49,182.83
NSEI:BIOCON DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= ₹23,137.29 × (1 + 7.55%) ÷ (18.67% – 7.55%)
₹223,833.09
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ₹223,833.09 ÷ (1 + 18.67%)10
₹40,421.68
NSEI:BIOCON Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ₹49,182.83 + ₹40,421.68
₹89,604.51
Equity Value per Share
(INR)
= Total value / Shares Outstanding
= ₹89,604.51 / 590.99
₹151.62
NSEI:BIOCON Discount to Share Price
Calculation Result
Value per share (INR) From above. ₹151.62
Current discount Discount to share price of ₹510.60
= -1 x (₹510.60 - ₹151.62) / ₹151.62
-236.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Biocon is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Biocon's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Biocon's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NSEI:BIOCON PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in INR ₹15.30
NSEI:BIOCON Share Price ** NSEI (2019-05-23) in INR ₹510.6
Asia Biotechs Industry PE Ratio Median Figure of 7 Publicly-Listed Biotechs Companies 24.07x
India Market PE Ratio Median Figure of 2,766 Publicly-Listed Companies 15.4x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Biocon.

NSEI:BIOCON PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NSEI:BIOCON Share Price ÷ EPS (both in INR)

= 510.6 ÷ 15.30

33.37x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biocon is overvalued based on earnings compared to the Asia Biotechs industry average.
  • Biocon is overvalued based on earnings compared to the India market.
Price based on expected Growth
Does Biocon's expected growth come at a high price?
Raw Data
NSEI:BIOCON PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 33.37x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts
19.4%per year
Global Biotechs Industry PEG Ratio Median Figure of 57 Publicly-Listed Biotechs Companies 1.27x
India Market PEG Ratio Median Figure of 558 Publicly-Listed Companies 1.3x

*Line of best fit is calculated by linear regression .

NSEI:BIOCON PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 33.37x ÷ 19.4%

1.72x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biocon is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Biocon's assets?
Raw Data
NSEI:BIOCON PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in INR ₹103.01
NSEI:BIOCON Share Price * NSEI (2019-05-23) in INR ₹510.6
India Biotechs Industry PB Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 2.07x
India Market PB Ratio Median Figure of 3,639 Publicly-Listed Companies 1.04x
NSEI:BIOCON PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NSEI:BIOCON Share Price ÷ Book Value per Share (both in INR)

= 510.6 ÷ 103.01

4.96x

* Primary Listing of Biocon.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biocon is overvalued based on assets compared to the IN Biotechs industry average.
X
Value checks
We assess Biocon's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Biocon has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BIOCON Future Performance

 How is Biocon expected to perform in the next 1 to 3 years based on estimates from 17 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Biocon expected to grow at an attractive rate?
  • Biocon's earnings growth is expected to exceed the low risk savings rate of 7.6%.
Growth vs Market Checks
  • Biocon's earnings growth is expected to exceed the India market average.
  • Biocon's revenue growth is expected to exceed the India market average.
Annual Growth Rates Comparison
Raw Data
NSEI:BIOCON Future Growth Rates Data Sources
Data Point Source Value (per year)
NSEI:BIOCON Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts 19.4%
NSEI:BIOCON Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 17 Analysts 20.2%
Asia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 24%
Asia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 44.3%
India Market Earnings Growth Rate Market Cap Weighted Average 17.1%
India Market Revenue Growth Rate Market Cap Weighted Average 10.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NSEI:BIOCON Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NSEI:BIOCON Future Estimates Data
Date (Data in INR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-03-31 104,982 27,527 18,291 3
2021-03-31 86,515 17,410 13,332 16
2020-03-31 70,923 12,156 9,830 17
NSEI:BIOCON Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2019-03-31 55,144 9,053
2018-12-31 51,551 8,220
2018-09-30 46,722 6,967
2018-06-30 43,198 4,108
2018-03-31 41,234 6,621 3,724
2017-12-31 38,792 3,695
2017-09-30 38,589 4,489
2017-06-30 38,361 5,268
2017-03-31 38,911 6,400 6,121
2016-12-31 40,487 11,633
2016-09-30 38,110 10,961
2016-06-30 36,539 9,388

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Biocon's earnings are expected to grow by 19.4% yearly, however this is not considered high growth (20% yearly).
  • Biocon's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NSEI:BIOCON Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below

All data from Biocon Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:BIOCON Future Estimates Data
Date (Data in INR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-03-31 28.70 30.71 26.69 2.00
2021-03-31 23.02 32.70 18.60 14.00
2020-03-31 16.93 21.40 12.78 15.00
NSEI:BIOCON Past Financials Data
Date (Data in INR Millions) EPS *
2019-03-31 15.30
2018-12-31 13.91
2018-09-30 11.79
2018-06-30 6.96
2018-03-31 6.31
2017-12-31 6.26
2017-09-30 7.62
2017-06-30 8.94
2017-03-31 10.39
2016-12-31 19.40
2016-09-30 18.28
2016-06-30 15.65

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Biocon is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Biocon's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Asia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Asia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Biocon has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BIOCON Past Performance

  How has Biocon performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Biocon's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Biocon's year on year earnings growth rate has been positive over the past 5 years.
  • Biocon's 1-year earnings growth exceeds its 5-year average (143.1% vs 6.5%)
  • Biocon's earnings growth has exceeded the Asia Biotechs industry average in the past year (143.1% vs 36.5%).
Earnings and Revenue History
Biocon's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Biocon Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:BIOCON Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 55,144.00 9,053.00 11,653.00 -2,699.00
2018-12-31 51,551.00 8,220.00 11,087.00 -2,421.00
2018-09-30 46,722.00 6,967.00 10,496.00 -2,449.00
2018-06-30 43,198.00 4,108.00 9,862.00 -1,993.00
2018-03-31 41,234.00 3,724.00 9,381.00 -1,747.00
2017-12-31 38,792.00 3,695.00 8,708.00 -1,522.00
2017-09-30 38,589.00 4,489.00 8,297.00 -1,257.00
2017-06-30 38,361.00 5,268.00 7,846.00 -1,324.00
2017-03-31 38,911.00 6,121.00 7,510.00 -1,283.00
2016-12-31 40,487.00 11,633.00 7,458.00 -1,472.00
2016-09-30 38,110.00 10,961.00 7,038.00 -1,468.00
2016-06-30 36,539.00 9,388.00 6,665.00 -1,378.00
2016-03-31 33,474.00 5,504.00 6,128.00 -1,320.00
2015-12-31 32,997.00 7,367.00 8,595.00 -202.00
2015-09-30 32,324.50 7,246.50 8,365.80 -195.90
2015-06-30 31,528.40 5,207.30 8,222.80 -272.10
2015-03-31 30,898.00 4,974.00 5,371.00 -1,321.00
2014-12-31 29,806.50 4,090.50 7,565.00 -386.20
2014-09-30 29,168.30 4,231.10 7,359.70 -561.30
2014-06-30 29,013.50 4,232.10 7,136.90 -585.40
2014-03-31 28,773.00 4,138.00 7,035.00 -642.00
2013-12-31 28,179.50 5,493.30 6,636.30 47.00
2013-09-30 27,510.10 5,361.00 6,427.60 47.00
2013-06-30 26,083.00 5,229.00 6,232.00 47.00
2013-03-31 24,853.00 5,089.00 6,002.00 47.00
2012-12-31 24,236.60 3,580.10 5,379.90 274.00
2012-09-30 23,060.30 3,511.00 5,224.50 274.00
2012-06-30 22,195.00 3,474.00 5,037.00 274.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Biocon has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Biocon used its assets more efficiently than the Asia Biotechs industry average last year based on Return on Assets.
  • Biocon has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Biocon's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Biocon has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BIOCON Health

 How is Biocon's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Biocon's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Biocon is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Biocon's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Biocon's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Biocon Company Filings, last reported 1 month ago.

NSEI:BIOCON Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 67,069.00 18,028.00 22,731.00
2018-12-31 61,891.00 21,166.00 21,872.00
2018-09-30 61,891.00 21,166.00 21,872.00
2018-06-30 56,485.00 22,831.00 19,339.00
2018-03-31 56,485.00 22,831.00 19,339.00
2017-12-31 55,149.00 21,219.00 19,978.00
2017-09-30 53,509.00 22,667.00 21,105.00
2017-06-30 53,155.00 22,903.00 22,616.00
2017-03-31 52,138.00 23,849.00 21,090.00
2016-12-31 49,800.00 25,450.00 24,900.00
2016-09-30 47,484.00 24,443.00 25,441.00
2016-06-30 43,668.00 25,032.00 23,499.00
2016-03-31 42,996.00 25,032.00 24,130.00
2015-12-31 40,670.00 11,970.00 10,790.00
2015-09-30 39,334.50 11,939.30 13,835.70
2015-06-30 35,820.00 10,200.00 10,470.00
2015-03-31 34,428.00 11,274.00 11,680.00
2014-12-31 33,630.00 11,660.00 8,880.00
2014-09-30 32,831.20 11,829.60 10,899.70
2014-06-30 32,210.00 9,310.00 13,440.00
2014-03-31 31,090.00 8,638.00 15,049.00
2013-12-31 31,120.00 5,370.00 10,490.00
2013-09-30 30,005.50 4,044.70 11,341.10
2013-06-30 28,820.00 3,740.00 12,850.00
2013-03-31 27,599.00 2,715.00 11,955.00
2012-12-31 25,500.00 2,570.00 9,750.00
2012-09-30 24,516.30 2,545.20 7,458.40
2012-06-30 23,560.00 2,050.00 8,870.00
  • Biocon's level of debt (26.9%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (27.8% vs 26.9% today).
  • Debt is well covered by operating cash flow (36.7%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 13.3x coverage).
X
Financial health checks
We assess Biocon's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Biocon has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BIOCON Dividends

 What is Biocon's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.2%
Current annual income from Biocon dividends. Estimated to be 0.59% next year.
If you bought ₹2,000 of Biocon shares you are expected to receive ₹4 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Biocon's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.54%).
  • Biocon's dividend is below the markets top 25% of dividend payers in India (2%).
Upcoming dividend payment

Purchase Biocon before the 'Buy Limit' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NSEI:BIOCON Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
Asia Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 6 Stocks 0.6%
India Market Average Dividend Yield Market Cap Weighted Average of 1409 Stocks 1.4%
India Minimum Threshold Dividend Yield 10th Percentile 0.3%
India Bottom 25% Dividend Yield 25th Percentile 0.5%
India Top 25% Dividend Yield 75th Percentile 2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NSEI:BIOCON Future Dividends Estimate Data
Date (Data in ₹) Dividend per Share (annual) Avg. No. Analysts
2022-03-31 3.38 3.00
2021-03-31 3.05 12.00
2020-03-31 2.84 13.00
NSEI:BIOCON Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2019-04-25 1.000 0.183
2018-04-26 1.000 0.160
2017-06-22 1.000 0.227
2016-06-06 1.667 0.537
2016-04-26 1.667 0.790
2016-03-11 1.667 0.985
2015-06-23 1.667 1.077
2015-04-30 1.667 1.118
2014-07-30 1.667 1.108
2013-07-30 1.667 1.222
2012-07-27 1.667 1.803
2011-04-28 1.500 1.569
2011-01-20 1.000 0.878
2010-10-22 1.000 0.740
2010-07-28 1.167 0.990

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biocon is not paying a notable dividend for India, therefore no need to check if the payments are stable.
  • Biocon is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Biocon's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Biocon's dividends as it is not paying a notable one for India.
Future Payout to shareholders
  • Dividends after 3 years are expected to be thoroughly covered by earnings (7.9x coverage).
X
Income/ dividend checks
We assess Biocon's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Biocon afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Biocon has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BIOCON Management

 What is the CEO of Biocon's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Arun Chandavarkar
COMPENSATION ₹37,600,000
AGE 57
TENURE AS CEO 4.8 years
CEO Bio

Dr. Arun Suresh Chandavarkar, B.Tech., M.S., PhD(Chem Eng) has been Chief Executive Officer and Joint Managing Director of Biocon Limited since April 24, 2014 and Executive Director since July 25, 2014. Dr. Chandavarkar served as the Chief Operating Officer of Biocon Ltd. from April 2006 to April 24, 2014. He served as the President of Operations and Technology of Biocon Ltd. He served as General Manager of Operations at Bioncon Ltd. since joining in 1990. He completed his B Tech. in Chemical Engineering from the Indian Institute of Technology, Mumbai in 1984 and was awarded a Ph.D. in BioChemical Engineering from the Massachusetts Institute of Technology, Cambridge, USA in 1990.

CEO Compensation
  • Arun's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Arun's remuneration is about average for companies of similar size in India.
Management Team Tenure

Average tenure and age of the Biocon management team in years:

4.8
Average Tenure
51
Average Age
  • The tenure for the Biocon management team is about average.
Management Team

Kiran Mazumdar-Shaw

TITLE
Founder
COMPENSATION
₹23M
AGE
65

Arun Chandavarkar

TITLE
CEO, Joint MD & Executive Director
COMPENSATION
₹38M
AGE
57
TENURE
4.8 yrs

Siddharth Mittal

TITLE
President of Finance
AGE
40
TENURE
4.8 yrs

Seema Ahuja

TITLE
VP & Global Head of Corporate Communications
AGE
52

Rakesh Bhasin

TITLE
Vice President

Sundaresan Raman

TITLE
Vice President

Saurabh Paliwal

TITLE
Head of Investor Relations

Amitava Saha

TITLE
President of Human Resources
COMPENSATION
₹7M
AGE
48
TENURE
3.6 yrs

Sandeep Rao

TITLE
Senior Vice President
AGE
45

B. S. Prasad

TITLE
Chief Operating Officer of Biocon Generics & APIs
AGE
51
Board of Directors Tenure

Average tenure and age of the Biocon board of directors in years:

7.6
Average Tenure
65
Average Age
  • The tenure for the Biocon board of directors is about average.
Board of Directors

Arun Chandavarkar

TITLE
CEO, Joint MD & Executive Director
COMPENSATION
₹38M
AGE
57
TENURE
5.1 yrs

John Mccallum Shaw

TITLE
Vice Chairman
COMPENSATION
₹26M
AGE
69

Kiran Mazumdar-Shaw

TITLE
Founder
COMPENSATION
₹23M
AGE
65
TENURE
14.1 yrs

John Russell Walls

TITLE
Independent & Non-Executive Director
COMPENSATION
₹4M
AGE
74
TENURE
8.1 yrs

Mary Harney

TITLE
Independent & Non-Executive Director
COMPENSATION
₹4M
AGE
65
TENURE
7.1 yrs

Dan Bradbury

TITLE
Independent & Non-Executive Director
COMPENSATION
₹3M
AGE
57
TENURE
6.1 yrs

Ravi Mazumdar

TITLE
Non-Independent & Non-Executive Director
COMPENSATION
₹400K
AGE
63
TENURE
18.8 yrs

Zan Fleming

TITLE
Member of Scientific Advisory Board

Harold Lebovitz

TITLE
Member of Scientific Advisory Board

Alan Cherrington

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • Biocon insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
28. Mar 19 Buy Biocon Ltd., ESOP Company 27. Mar 19 27. Mar 19 100,000 ₹613.99 ₹61,399,364
25. Mar 19 Buy Biocon Ltd., ESOP Company 25. Mar 19 25. Mar 19 750,000 ₹611.50 ₹458,624,513
22. Mar 19 Sell Arshad Jamil Individual 18. Mar 19 20. Mar 19 -24,750 ₹630.74 ₹-15,610,821
20. Mar 19 Sell Gopi Srinivasan Individual 19. Mar 19 19. Mar 19 -8,000 ₹631.01 ₹-5,048,108
20. Mar 19 Sell V. Jaikanth Individual 19. Mar 19 19. Mar 19 -1,000 ₹630.00 ₹-630,000
20. Mar 19 Sell G. Radhakrishnan Individual 19. Mar 19 20. Mar 19 -7,081 ₹636.00 ₹-4,488,661
15. Mar 19 Buy Biocon Ltd., ESOP Company 14. Mar 19 14. Mar 19 26,131 ₹614.97 ₹16,069,876
12. Mar 19 Sell Yogesh Chaube Individual 06. Mar 19 06. Mar 19 -9,001 ₹629.41 ₹-5,665,319
08. Mar 19 Buy Biocon Ltd., ESOP Company 07. Mar 19 07. Mar 19 250,000 ₹614.66 ₹153,665,122
08. Mar 19 Sell G. Radhakrishnan Individual 27. Feb 19 01. Mar 19 -10,000 ₹627.50 ₹-6,274,999
27. Feb 19 Buy Biocon Ltd., ESOP Company 26. Feb 19 26. Feb 19 7,508 ₹611.82 ₹4,593,563
18. Feb 19 Sell Chigurupati Rao Individual 15. Feb 19 15. Feb 19 -1,000 ₹617.04 ₹-617,045
18. Feb 19 Buy Chigurupati Rao Individual 15. Feb 19 15. Feb 19 1,000 ₹613.50 ₹613,500
14. Feb 19 Sell Srinivasan Raman Individual 12. Feb 19 12. Feb 19 -20,000 ₹650.00 ₹-12,999,999
14. Feb 19 Sell Hitendra Chaudhary Individual 08. Feb 19 08. Feb 19 -980 ₹645.00 ₹-632,100
14. Feb 19 Sell Shreehas Tambe Individual 11. Feb 19 12. Feb 19 -16,307 ₹648.02 ₹-10,567,282
14. Feb 19 Sell Suresh Subramanian Individual 12. Feb 19 12. Feb 19 -2,000 ₹4,628.95 ₹-9,257,909
12. Feb 19 Sell M. Elango Individual 07. Feb 19 08. Feb 19 -13,400 ₹657.75 ₹-8,809,216
12. Feb 19 Sell Veena Vasanth Individual 15. Jan 19 08. Feb 19 -2,300 ₹660.00 ₹-1,515,750
07. Feb 19 Sell Vasu Raghavan Individual 01. Feb 19 04. Feb 19 -2,000 ₹661.50 ₹-1,323,005
07. Feb 19 Sell Maneesh Ghildyal Individual 05. Feb 19 05. Feb 19 -1,000 ₹654.00 ₹-654,000
05. Feb 19 Sell Arthur Augustine Individual 03. Dec 18 04. Feb 19 -15,994 ₹666.46 ₹-10,651,051
05. Feb 19 Sell K. Sivanandam Individual 01. Feb 19 01. Feb 19 -500 ₹665.00 ₹-332,500
05. Feb 19 Sell Palle Acharyulu Individual 02. Feb 19 02. Feb 19 -3,000 ₹663.26 ₹-1,989,769
07. Feb 19 Sell Partha Hazra Individual 28. Jan 19 01. Feb 19 -2,500 ₹652.50 ₹-1,629,493
04. Feb 19 Sell Harish Pai Individual 31. Jan 19 31. Jan 19 -6,200 ₹645.46 ₹-4,001,842
04. Feb 19 Sell V. Gururaj Individual 14. Dec 18 14. Dec 18 -12,066 ₹650.96 ₹-7,854,440
04. Feb 19 Sell Vijaya Reddy Individual 01. Feb 19 01. Feb 19 -9,000 ₹661.26 ₹-5,951,366
04. Feb 19 Sell Hitendra Chaudhary Individual 01. Feb 19 01. Feb 19 -16,500 ₹641.00 ₹-10,576,500
01. Feb 19 Sell Ritesh Sharma Individual 29. Jan 19 29. Jan 19 -10,000 ₹650.01 ₹-6,500,099
01. Feb 19 Sell Hari Prasad Individual 29. Jan 19 01. Feb 19 -3,350 ₹659.89 ₹-2,193,825
01. Feb 19 Sell Sudhir Nayak Individual 28. Jan 19 28. Jan 19 -22,500 ₹650.00 ₹-14,624,999
23. Jan 19 Sell Ashwin Vora Individual 11. Jan 19 18. Jan 19 -2,000 ₹490.50 ₹-981,000
03. Jan 19 Sell Abhijit Zutshi Individual 24. Dec 18 24. Dec 18 -33,900 ₹618.13 ₹-20,954,773
03. Jan 19 Sell Vivek Gupta Individual 07. Sep 18 20. Dec 18 -2,350 ₹669.57 ₹-1,573,489
24. Dec 18 Sell Ankur Bhatnagar Individual 17. Dec 18 19. Dec 18 -4,000 ₹641.75 ₹-2,567,000
24. Dec 18 Sell Vandana Singh Individual 19. Dec 18 20. Dec 18 -400 ₹642.50 ₹-257,000
24. Dec 18 Sell Renuka Ganesh Individual 20. Dec 18 20. Dec 18 -13,500 ₹635.74 ₹-8,582,541
18. Dec 18 Sell Maneesh Ghildyal Individual 14. Dec 18 14. Dec 18 -1,000 ₹652.15 ₹-652,150
18. Dec 18 Sell Amitava Saha Individual 12. Dec 18 14. Dec 18 -2,000 ₹645.00 ₹-1,290,000
15. Dec 18 Sell Maneesh Ghildyal Individual 13. Dec 18 13. Dec 18 -2,600 ₹640.48 ₹-1,665,240
15. Dec 18 Sell Santosh Kumar Individual 12. Dec 18 12. Dec 18 -5,625 ₹640.00 ₹-3,600,000
15. Dec 18 Sell Vandana Singh Individual 13. Dec 18 14. Dec 18 -600 ₹648.00 ₹-388,800
15. Dec 18 Sell Vikram Kumar Individual 13. Dec 18 13. Dec 18 -9,200 ₹639.41 ₹-5,882,563
11. Dec 18 Buy Biocon Ltd., ESOP Company 07. Dec 18 10. Dec 18 250,000 ₹611.38 ₹152,845,840
07. Dec 18 Sell Karthik Ramani Individual 05. Dec 18 05. Dec 18 -6,000 ₹627.54 ₹-3,765,240
07. Dec 18 Sell Amitava Saha Individual 30. Nov 18 05. Dec 18 -6,000 ₹621.35 ₹-3,728,117
05. Dec 18 Sell Ravi Shankar P Individual 04. Dec 18 04. Dec 18 -1,500 ₹623.50 ₹-935,250
05. Dec 18 Sell Prasad Ravishankar Individual 04. Dec 18 04. Dec 18 -1,500 ₹623.50 ₹-935,250
29. Nov 18 Sell Sumit Bhanot Individual 26. Nov 18 26. Nov 18 -27,000 ₹614.55 ₹-16,592,850
20. Sep 18 Sell S. Krishnan Individual 18. Sep 18 18. Sep 18 -5,800 ₹678.90 ₹-3,937,620
20. Nov 18 Sell Renukaradhya Tv Individual 14. Nov 18 14. Nov 18 -4,000 ₹619.00 ₹-2,476,000
28. Sep 18 Sell M. Elango Individual 27. Sep 18 27. Sep 18 -7,000 ₹704.26 ₹-4,929,820
18. Jun 18 Sell M. Elango Individual 12. Jun 18 12. Jun 18 -17,500 ₹609.00 ₹-10,657,500
24. Sep 18 Sell A. Suman Individual 21. Sep 18 21. Sep 18 -4,500 ₹690.00 ₹-3,105,000
07. Sep 18 Sell A. Suman Individual 06. Sep 18 06. Sep 18 -2,500 ₹609.35 ₹-1,523,375
14. Nov 18 Sell Abhishek Kulshrestha Individual 12. Nov 18 12. Nov 18 -2,400 ₹629.58 ₹-1,511,000
12. Nov 18 Sell Maneesh Ghildyal Individual 09. Nov 18 12. Nov 18 -6,000 ₹640.78 ₹-3,828,752
05. Nov 18 Sell Karthik Ramani Individual 31. Oct 18 31. Oct 18 -11,250 ₹653.05 ₹-7,346,812
12. Oct 18 Sell Girija Kelath Individual 01. Oct 18 01. Oct 18 -15,000 ₹670.00 ₹-10,050,000
10. Oct 18 Sell Vishwamabhara Rai Individual 27. Sep 18 27. Sep 18 -1,000 ₹705.00 ₹-705,000
10. Oct 18 Sell Harish Pai Individual 24. Sep 18 24. Sep 18 -6,270 ₹672.79 ₹-4,218,392
05. Oct 18 Sell Sreesha Srinivasa Individual 14. Aug 18 28. Sep 18 -1,750 ₹702.32 ₹-1,229,060
05. Oct 18 Sell Vandana Singh Individual 31. Aug 18 28. Sep 18 -3,550 ₹666.76 ₹-2,367,000
01. Oct 18 Sell Melarkode Ramakrishnan Individual 28. Sep 18 28. Sep 18 -5,000 ₹706.00 ₹-3,530,000
28. Sep 18 Sell S. Rajeev Individual 25. Sep 18 25. Sep 18 -5,888 ₹694.92 ₹-4,091,712
28. Sep 18 Sell Unnikrishnan M. Individual 26. Sep 18 26. Sep 18 -2,000 ₹711.68 ₹-1,423,366
28. Sep 18 Sell Renukaradhya Tv Individual 30. Jul 18 25. Sep 18 -5,000 ₹697.00 ₹-3,485,000
28. Sep 18 Sell P. Muralidharan Individual 26. Sep 18 26. Sep 18 -500 ₹716.00 ₹-358,000
28. Sep 18 Sell Pradip Nair Individual 25. Sep 18 26. Sep 18 -3,000 ₹710.07 ₹-2,130,214
28. Sep 18 Sell Biocon Ltd., ESOP Company 25. Sep 18 25. Sep 18 -175,600 ₹152.88 ₹-26,845,559
28. Sep 18 Sell Suresh Subramanian Individual 27. Sep 18 27. Sep 18 -2,000 ₹703.10 ₹-1,406,202
27. Sep 18 Sell A. Kumar Individual 06. Sep 18 26. Sep 18 -3,850 ₹701.27 ₹-2,699,875
27. Sep 18 Sell Rajeshwari Vaidhyanathan Individual 25. Sep 18 25. Sep 18 -5,000 ₹692.20 ₹-3,461,000
27. Sep 18 Sell Shrivallabh Desai Individual 25. Sep 18 25. Sep 18 -1,500 ₹699.67 ₹-1,049,500
27. Sep 18 Sell H. Basavaraj Individual 25. Sep 18 25. Sep 18 -500 ₹700.04 ₹-350,018
27. Sep 18 Sell Arshad Jamil Individual 25. Sep 18 25. Sep 18 -1,000 ₹700.00 ₹-700,000
27. Sep 18 Sell Hari Prasad Individual 27. Sep 18 27. Sep 18 -1,000 ₹707.50 ₹-707,500
27. Sep 18 Sell V. Jaikanth Individual 25. Sep 18 25. Sep 18 -2,000 ₹700.00 ₹-1,400,000
27. Sep 18 Sell B Vedavyasachar Individual 25. Sep 18 25. Sep 18 -1,000 ₹700.00 ₹-700,000
27. Sep 18 Sell Maneesh Ghildyal Individual 21. Sep 18 25. Sep 18 -2,000 ₹685.57 ₹-1,371,150
27. Sep 18 Sell Suresh Subramanian Individual 25. Sep 18 25. Sep 18 -5,000 ₹693.89 ₹-3,469,454
27. Sep 18 Sell G. Radhakrishnan Individual 25. Sep 18 26. Sep 18 -5,000 ₹710.00 ₹-3,550,000
25. Sep 18 Sell Partha Hazra Individual 14. Sep 18 18. Sep 18 -2,000 ₹667.18 ₹-1,334,369
25. Sep 18 Sell Rajkamal Varshney Individual 21. Sep 18 24. Sep 18 -2,609 ₹672.88 ₹-1,755,555
25. Sep 18 Sell A. Chandrashekar Individual 25. Sep 18 25. Sep 18 -6,700 ₹696.00 ₹-4,663,200
25. Sep 18 Sell H Lakshmikantha Individual 21. Sep 18 21. Sep 18 -5,000 ₹675.20 ₹-3,375,976
25. Sep 18 Sell P. Muralidharan Individual 19. Sep 18 21. Sep 18 -1,000 ₹690.48 ₹-690,239
25. Sep 18 Sell V. Jaikanth Individual 18. Sep 18 18. Sep 18 -1,000 ₹683.00 ₹-683,000
25. Sep 18 Sell Suresh Subramanian Individual 18. Sep 18 21. Sep 18 -8,000 ₹687.20 ₹-5,497,619
24. Sep 18 Sell M. Anand Individual 17. Sep 18 18. Sep 18 -3,000 ₹670.78 ₹-2,012,343
24. Sep 18 Sell G. Radhakrishnan Individual 18. Sep 18 18. Sep 18 -16,730 ₹679.02 ₹-11,360,050
19. Sep 18 Sell Rajeshwari Vaidhyanathan Individual 14. Sep 18 14. Sep 18 -5,000 ₹661.26 ₹-3,306,277
19. Sep 18 Sell M Kumar Individual 14. Sep 18 14. Sep 18 -4,400 ₹659.80 ₹-2,903,100
19. Sep 18 Sell Raviraj Shetty Individual 07. Sep 18 07. Sep 18 -4,470 ₹633.34 ₹-2,831,010
19. Sep 18 Sell P. Muralidharan Individual 31. Aug 18 06. Sep 18 -12,000 ₹635.05 ₹-1,925,105
19. Sep 18 Sell Hari Prasad Individual 06. Sep 18 06. Sep 18 -1,000 ₹645.50 ₹-645,500
20. Sep 18 Sell Rajkamal Varshney Individual 17. Sep 18 18. Sep 18 -7,391 ₹674.99 ₹-4,988,866
20. Sep 18 Sell H. Basavaraj Individual 18. Sep 18 18. Sep 18 -2,000 ₹682.50 ₹-1,365,000
19. Sep 18 Sell Hari Prasad Individual 18. Sep 18 18. Sep 18 -2,000 ₹677.40 ₹-1,354,800
18. Sep 18 Sell Ankur Bhatnagar Individual 10. Sep 18 11. Sep 18 -3,000 ₹647.00 ₹-1,941,000
18. Sep 18 Sell Unnikrishnan M. Individual 11. Sep 18 11. Sep 18 -9,000 ₹656.08 ₹-5,904,721
18. Sep 18 Sell Rajkamal Varshney Individual 14. Sep 18 14. Sep 18 -3,000 ₹662.92 ₹-1,988,769
18. Sep 18 Sell Saurabh Paliwal Individual 18. Sep 18 18. Sep 18 -10,126 ₹680.67 ₹-6,892,430
19. Sep 18 Sell Prasanna Sampath Individual 06. Sep 18 07. Sep 18 -13,500 ₹660.51 ₹-8,916,932
19. Sep 18 Sell M Kumar Individual 14. Sep 18 14. Sep 18 -4,400 ₹659.80 ₹-2,903,100
17. Sep 18 Sell P. Muralidharan Individual 31. Aug 18 06. Sep 18 -3,000 ₹655.00 ₹-1,925,106
11. Sep 18 Sell Adithi Devarajan Individual 06. Sep 18 07. Sep 18 -7,700 ₹668.35 ₹-5,146,270
11. Sep 18 Sell Ajay Khanna Individual 31. Aug 18 07. Sep 18 -9,000 ₹641.89 ₹-5,777,004
11. Sep 18 Sell B. Kumar Individual 21. Aug 18 07. Sep 18 -4,050 ₹650.69 ₹-2,635,301
11. Sep 18 Sell H Lakshmikantha Individual 06. Sep 18 06. Sep 18 -5,000 ₹630.66 ₹-3,153,284
11. Sep 18 Sell Palle Acharyulu Individual 05. Sep 18 05. Sep 18 -6,400 ₹625.83 ₹-4,005,312
07. Sep 18 Sell Rajkamal Varshney Individual 03. Sep 18 03. Sep 18 -1,000 ₹609.35 ₹-609,350
05. Sep 18 Sell Milind Dalal Individual 31. Aug 18 31. Aug 18 -2,200 ₹622.49 ₹-1,369,469
05. Sep 18 Sell Rajkamal Varshney Individual 30. Aug 18 31. Aug 18 -5,000 ₹618.93 ₹-3,094,670
05. Sep 18 Sell Rajeshwari Vaidhyanathan Individual 20. Aug 18 28. Aug 18 -2,000 ₹607.97 ₹-1,215,944
05. Sep 18 Sell Vasu Raghavan Individual 24. Aug 18 31. Aug 18 -5,700 ₹614.10 ₹-3,500,357
28. Aug 18 Sell Arshad Jamil Individual 23. Aug 18 23. Aug 18 -2,250 ₹613.49 ₹-1,380,352
28. Aug 18 Sell S. Shanmugam Individual 21. Aug 18 21. Aug 18 -2,500 ₹603.00 ₹-1,507,500
28. Aug 18 Sell Arshad Jamil Individual 23. Aug 18 23. Aug 18 -2,250 ₹613.49 ₹-1,380,353
24. Aug 18 Sell Mukesh Kamat Individual 21. Aug 18 21. Aug 18 -2,000 ₹608.50 ₹-1,217,000
24. Aug 18 Sell Amitava Saha Individual 17. Aug 18 17. Aug 18 -10,010 ₹595.63 ₹-5,962,276
20. Aug 18 Sell Mukesh Kamat Individual 16. Aug 18 20. Aug 18 -8,000 ₹808.87 ₹-5,090,260
10. Aug 18 Sell Amitava Saha Individual 31. Jul 18 06. Aug 18 -3,000 ₹575.00 ₹-1,725,000
07. Aug 18 Sell A. Kameswararao Individual 03. Aug 18 03. Aug 18 -16,000 ₹595.36 ₹-9,525,802
07. Aug 18 Buy Suresh Talwar Individual 02. Aug 18 02. Aug 18 4,000 ₹588.72 ₹2,354,890
01. Aug 18 Sell Chigurupati Rao Individual 15. Jun 18 23. Jul 18 -7,000 ₹629.01 ₹-4,163,668
01. Aug 18 Buy Chigurupati Rao Individual 15. Jun 18 23. Jul 18 7,000 ₹629.42 ₹4,134,884
30. Jul 18 Sell Swanana Palsule Individual 27. Jul 18 27. Jul 18 -6,328 ₹586.85 ₹-3,713,587
26. Jul 18 Buy Nihal Goerge Individual 03. May 18 01. Jun 18 2,150 ₹646.99 ₹1,374,122
24. Jul 18 Sell Raviraj Shetty Individual 20. Jun 18 20. Jun 18 -2,000 ₹616.30 ₹-1,232,600
24. Jul 18 Sell Renuka Ganesh Individual 01. Jun 18 01. Jun 18 -5,028 ₹643.52 ₹-3,235,637
03. Jul 18 Sell Amitava Saha Individual 26. Jun 18 27. Jun 18 -2,000 ₹638.81 ₹-1,277,618
14. Jun 18 Sell S. Shanmugam Individual 11. Jun 18 11. Jun 18 -6,000 ₹613.00 ₹-3,678,000
27. Jun 18 Sell Mukesh Kamat Individual 26. Jun 18 26. Jun 18 -8,500 ₹636.47 ₹-5,409,994
27. Jun 18 Sell Adithi Devarajan Individual 08. Jun 18 25. Jun 18 -4,490 ₹628.56 ₹-2,822,240
27. Jun 18 Sell Amitava Saha Individual 14. Jun 18 22. Jun 18 -2,000 ₹622.65 ₹-1,245,294
27. Jun 18 Sell Saurabh Paliwal Individual 25. Jun 18 25. Jun 18 -13,497 ₹641.95 ₹-8,664,448
26. Jun 18 Sell Sagiri Babu Individual 22. Jun 18 22. Jun 18 -6,000 ₹626.55 ₹-3,759,280
25. Jun 18 Sell Mukesh Kamat Individual 22. Jun 18 22. Jun 18 -1,630 ₹625.00 ₹-1,018,750
25. Jun 18 Sell Arshad Jamil Individual 22. Jun 18 22. Jun 18 -3,000 ₹630.00 ₹-1,890,000
21. Jun 18 Sell Mukesh Kamat Individual 20. Jun 18 21. Jun 18 -2,000 ₹625.00 ₹-1,247,568
20. Jun 18 Sell Arshad Jamil Individual 15. Jun 18 15. Jun 18 -5,000 ₹623.00 ₹-3,115,000
20. Jun 18 Sell Amitava Saha Individual 14. Jun 18 14. Jun 18 -1,000 ₹613.00 ₹-613,000
20. Jun 18 Sell Mukesh Kamat Individual 15. Jun 18 20. Jun 18 -1,600 ₹625.90 ₹-1,001,446
18. Jun 18 Sell Sagiri Babu Individual 08. May 18 13. Jun 18 -2,000 ₹617.90 ₹-1,235,800
11. Jun 18 Buy Biocon Ltd., ESOP Company 06. Jun 18 06. Jun 18 68,000 ₹607.49 ₹41,309,617
06. Jun 18 Sell Palle Acharyulu Individual 28. May 18 28. May 18 -8,000 ₹658.73 ₹-5,269,800
06. Jun 18 Buy Biocon Ltd., ESOP Company 05. Jun 18 05. Jun 18 33,255 ₹597.61 ₹19,873,415
05. Jun 18 Sell Rohit Markhedkar Individual 01. Jun 18 01. Jun 18 -3,960 ₹650.00 ₹-2,574,000
28. May 18 Buy Biocon Ltd., ESOP Company 24. May 18 25. May 18 78,735 ₹641.83 ₹50,534,110
X
Management checks
We assess Biocon's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Biocon has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BIOCON News

Simply Wall St News

Should We Worry About Biocon Limited's (NSE:BIOCON) P/E Ratio?

This article is written for those who want to get better at using price to earnings ratios (P/E ratios). … We'll show how you can use Biocon Limited's (NSE:BIOCON) P/E ratio to inform your assessment of the investment opportunity. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Simply Wall St -

How Should Investors Feel About Biocon Limited's (NSE:BIOCON) CEO Pay?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Arun Chandavarkar's Compensation Compare With Similar Sized Companies. … So Arun Chandavarkar receives a similar amount to the median CEO pay, amongst the companies we looked at.

Simply Wall St -

Biocon Limited (NSE:BIOCON): What Is Driving Earnings Margins?

With analysts expecting … Biocon Limited (NSE:BIOCON) to … earnings growth of 40.41% annualised

Simply Wall St -

Who Just Ramped Up Their Shares In Biocon Limited (NSE:BIOCON)?

Biocon's insiders have invested. … A well-known argument is that insiders investing more in their own companies’ shares sends an optimistic signal … A research published in The MIT Press (1998) concluded that stocks following insider buying outperformed the market by 4.5%.

Simply Wall St -

What Should Investors Know About Biocon Limited's (NSE:BIOCON) Future?

Based on Biocon Limited's (NSE:BIOCON) earnings update in March 2018, … with profits predicted to ramp up by an impressive 59.18% next year, … 5-year average growth rate of 9.36%.

Simply Wall St -

These Factors Make Biocon Limited (NSE:BIOCON) A Great Investment

Biocon Limited (NSE:BIOCON) is a stock with outstanding fundamental characteristics. … When we build an investment case, we need to look at the stock with a holistic perspective. … In the case of BIOCON, it.

Simply Wall St -

Biocon Limited's (NSE:BIOCON) Earnings Dropped -39.16%, Did Its Industry Show Weakness Too?

Check out our latest analysis for Biocon Commentary On BIOCON's Past Performance To account for any quarterly or half-yearly updates, I use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … For Biocon, its latest earnings (trailing twelve month) is ₹3.72B, which, in comparison to last year’s level, has declined by a substantial -39.16%. … Given that these values may be somewhat short-term thinking, I have computed an annualized five-year value for Biocon's earnings, which stands at ₹5.30B This doesn't look much better, as earnings seem to have gradually been diminishing over time.

Simply Wall St -

Why Biocon Limited (NSE:BIOCON) Is A Financially Healthy Company

This article will examine BIOCON’s financial liquidity and debt levels to get an idea of whether the company can deal with cyclical downturns and maintain funds to accommodate strategic spending for future growth. … See our latest analysis for Biocon How does BIOCON’s operating cash flow stack up against its debt? … Next Steps: BIOCON’s cash flow coverage indicates it could improve its operating efficiency in order to meet demand for debt repayments should unforeseen events arise.

Simply Wall St -

Biocon Limited (NSE:BIOCON): What Is Driving Earnings Margins?

Check out our latest analysis for Biocon A closer look at BIOCON's profit margin In general, the value that accrues to equity holders is partly reliant on the ability of a company to convert sales revenue in to earnings. … Knowing the portion of top line revenue that is turned into net income helps to assess this ability whilst spotting profit drivers, and can be found by calculating BIOCON's profit margin. … Margin Calculation for BIOCON Profit Margin = Net Income ÷ Revenue ∴ Profit Margin = 3.70 Billion ÷ 38.79 Billion = 9.53% Biocon's margin has expanded in the past five years, due to 11.34% in average net income growth surpassing a 8.08% average growth in revenue, which means that the previous increase in revenue has coincided with a larger portion falling to the bottom line.

Simply Wall St -

Does Biocon Limited's (NSE:BIOCON) March Stock Price Reflect Its Future Growth?

Biocon Limited (NSEI:BIOCON) is a stock well-positioned for future growth, but many investors are wondering whether its last closing price of ₹622.9 is based on unrealistic expectations. … Biocon is available at price-to-earnings ratio of 99.46x, showing us it is undervalued based on its latest annual earnings update compared to the biotechs average of 99.46x , and overvalued compared to the IN market average ratio of 25.26x. … A PE ratio of 99.46x and expected year-on-year earnings growth of 38.89% give Biocon a quite high PEG ratio of 2.56x.

Simply Wall St -

BIOCON Company Info

Description

Biocon Limited, a biopharmaceutical company, develops, manufactures, and sells biopharmaceuticals for diabetes, cancer, and autoimmune conditions. It operates through Small Molecule APIs & Generic Formulations, Biologics, Branded Formulations, and Research Services segments. The company provides biosimilars comprising recombinant human insulin, insulin glargine, insulin lispro, insulin aspart, and monoclonal antibodies and other biologics; small molecules; and provides branded formulation products under the Insugen, Basalog, BIOMAb EGFR, CANMAb, and ALZUMAb brands. In addition, it is involved in the integrated discovery, development, and manufacturing services for novel molecules, including small molecules, large molecules, antibody-drug conjugates, and oligonucleotides. Further, the company offers botanical products. It serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.

Details
Name: Biocon Limited
BIOCON
Exchange: NSEI
Founded: 1978
₹306,342,233,887
590,994,953
Website: http://www.biocon.com
Address: Biocon Limited
20th KM, Hosur Road,
Electronics City,
Bengaluru,
Karnataka, 560100,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NSEI BIOCON Equity Shares National Stock Exchange of India IN INR 07. Apr 2004
BSE 532523 Equity Shares Mumbai Stock Exchange IN INR 07. Apr 2004
Number of employees
Current staff
Staff numbers
10,293
Biocon employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/23 12:51
End of day share price update: 2019/05/23 00:00
Last estimates confirmation: 2019/04/30
Last earnings filing: 2019/04/25
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.